Results for deferoxamine translation from English to Croatian

half of deferoxamine dose
polovica doze deferoksamina

one third of deferoxamine dose
jedna trećina doze deferoksamina

for patients well managed on deferoxamine
za bolesnike dobro održavane na deferoksaminu

the product information of deferoxamine should be consulted.
potrebno je proučiti informacije o lijeku deferoksamina.

in the initial study comparing ferriprox with deferoxamine, the average blood ferritin levels were similar in the two treatment groups.
u prvotnom ispitivanju u kojem je uspoređena primjena lijeka ferriprox s deferoksaminom, prosječne razine feritina u krvi bile su slične u dviju liječenih skupina.

however, there were too few patients in the study to prove whether or not such a schedule is as effective as deferoxamine taken on its own.
međutim, u ispitivanju je bilo premalo bolesnika da bi se moglo dokazati je li takav raspored jednako učinkovit kao i monoterapija deferoksaminom.

based on the reported adverse interaction that can occur between deferoxamine and vitamin c, caution should be used when administering deferiprone and vitamin c concurrently.
na temelju prijavljenih neželjenih interakcija koje mogu nastati između deferoksamina i vitamina c, potreban je oprez kod istodobne primjene deferiprona i vitamina c.

exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:
exjade je također indiciran za liječenje kroničnog preopterećenja željezom zbog transfuzija krvi kada je terapija deferoksaminom kontraindicirana ili neodgovarajuća u sljedećim skupinama bolesnika:

an additional study looked at the effectiveness of exjade in 184 patients who could not be treated with deferoxamine, including patients with beta thalassaemia major and with other types of anaemia.
provedeno je i dodatno ispitivanje u okviru kojega je razmatrana djelotvornost lijeka exjade, i to na 184 bolesnika koji se nisu mogli liječiti deferoksaminom, uključujući bolesnike s beta-talasemijom major i drugim vrstama anemije.

however, the average iron concentration in the liver of ferriprox- treated patients seemed to increase more than in deferoxamine-treated patients.
međutim, čini se da se prosječna koncentracija željeza u jetri u bolesnika koji su liječeni lijekom ferriprox povećala više no u bolesnika liječenih deferoksaminom.

however, when looking at the 381 patients who had particularly high levels of iron in their liver at the beginning of the study and who received comparable amounts of exjade and deferoxamine, the two medicines were as effective as each other.
međutim, kada se promatraju rezultati na 381 bolesniku koji su imali osobito visoke razine željeza u jetri na početku ispitivanja i koji su primili usporedive količine lijeka exjade i deferoksamina, oba ta lijeka bila su jednako djelotvorna.

doses of ferriprox in those studies ranged from 50 to 100 mg/kg/day and doses of deferoxamine from 40 to 60 mg/kg/day.
doze ferriproxa u tim ispitivanjima bile su u rasponu od 50 do 100 mg/kg/dan, a doze deferoksamina od 40 do 60 mg/kg/dan.

children aged 2 to 5 years with beta thalassaemia major who receive frequent blood transfusions, when deferoxamine (another medicine used to treat iron overload) cannot be used or is inadequate;
u djece u dobi od 2 do 5 godina s beta-talasemijom major koja često primaju transfuziju krvi u slučaju kada se deferoksamin (drugi lijek koji se koristi za liječenje preopterećenja željezom) ne može primjenjivati ili kada njegova primjena nije prikladna;

0.32 ± 3.38 absolute units (%) in the deferoxamine group (difference between groups; p=0.003).
3,07 ± 3,58 apsolutnih jedinica (%) u skupini koja je primala ferriprox i za 0,32 ± 3,38 apsolutnih jedinica (%) u skupini koja je primala deferoksamin (razlika između skupina; p=0,003).

a later study compared treatment alternating ferriprox and deferoxamine (five days’ ferriprox plus two days’ deferoxamine each week) with continuous treatment with deferoxamine on its own, in 60 patients over 12 months.
u kasnijem ispitivanju uspoređeno je naizmjenično liječenje lijekom ferriprox i deferoksaminom (pet dana primjene lijeka ferriprox i dva dana primjene deferoksamina svaki tjedan) s neprekinutom monoterapijom deferoksaminom u 60 bolesnika tijekom 12 mjeseci.